Mels Hoogendoorn

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater et al. · New England Journal of Medicine · 2023 · 291 citations · Full text

Medicine, Hematology, Oncology +16

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

Iris de Weerdt, Tom Hofland, Renate de Boer et al. · Blood Advances · 2019 · 107 citations · Full text

Life Sciences, Hematology, Immunology +17

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

Lieke H. van der Helm, Canan Alhan, Pierre W. Wijermans et al. · British Journal of Haematology · 2011 · 106 citations · Full text

Medicine, Hematology, Pharmacology +11

Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)

Pieternella J. Lugtenburg, Peter de Nully Brown, Bronno van der Holt et al. · Journal of Clinical Oncology · 2020 · 86 citations · Full text

Medicine, Oncology, Pharmacotherapy +7

Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study

André Wieringa, Karin Boslooper, Mels Hoogendoorn et al. · British Journal of Haematology · 2014 · 80 citations

Medicine, Hematology, Oncology +10